Ataxin 7 (ATXN7) (Middle Region) Peptide
ATXN7
Reactivité: Humain
Hôte: Synthetic
BP, WB
-
- Antigène Tous les produits ATXN7
- ATXN7 (Ataxin 7 (ATXN7))
- Protein Region
- Middle Region
- Origine
- Humain
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-ATXN7 antibody (Catalog #: ARP33364_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Antigène
- ATXN7 (Ataxin 7 (ATXN7))
- Synonymes
- MGC82940 Peptide, ADCAII Peptide, OPCA3 Peptide, SCA7 Peptide, A430107N12Rik Peptide, AI627028 Peptide, Sca7 Peptide, ataxin-7 Peptide, RGD1562692 Peptide, ataxin 7 L homeolog Peptide, ataxin 7 Peptide, atxn7.L Peptide, atxn7 Peptide, ATXN7 Peptide, Atxn7 Peptide
- Sujet
-
ATXN7 is involved in neurodegeneration. ATXN7 acts as component of the STAGA transcription coactivator-HAT complex. ATXN7 mediates the interaction of STAGA complex with the CRX and is involved in CRX-dependent gene activation.The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with Spinocerebellar ataxia-7, contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The exact function of this gene is not known, however, since the encoded protein contains a nuclear localization sequence, and is found to be localized in the nucleus, it has been postulated to be a potential transcription factor. Alternative splicing, resulting in transcript variants encoding different isoforms, has been noted for this gene.
Alias Symbols: ADCAII, OPCA3, SCA7
Protein Interaction Partner: CRX,KAT2A,PICK1,PSMC1,RAD23A,TAF10,TP53BP2,TRRAP,ATXN7L3,CRX,KAT2A,PSMC1,PSMC2,PSMC5,PSMC6,PSMD2,PSMD7,SUPT3H,TAF10,TAF12,TRRAP,USP22
Protein Size: 892 - Poids moléculaire
- 95 kDa
- ID gène
- 6314
- NCBI Accession
- NM_000333, NP_000324
- UniProt
- O15265
-
Vous êtes ici:
